Cathie Wood
DNA icon

Cathie Wood’s Ginkgo Bioworks DNA Stock Holding History

Cathie Wood’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-596,280
Closed -$7.97M – 189
2024
Q2 		$7.97M Sell
596,280
-4,143,893
-87% -$124M 0.07% 103
2024
Q1 		$220M Sell
4,740,173
-224,992
-5% -$11.6M 1.52% 21
2023
Q4 		$336M Buy
4,965,165
+410,360
+9% +$25.1M 1.99% 18
2023
Q3 		$330M Buy
4,554,805
+311,067
+7% +$24.9M 2.52% 14
2023
Q2 		$316M Buy
4,243,738
+124,813
+3% +$7.39M 2.09% 18
2023
Q1 		$219M Buy
4,118,925
+509,323
+14% +$32.3M 1.51% 21
2022
Q4 		$244M Buy
3,609,602
+439,131
+14% +$40.4M 2.11% 17
2022
Q3 		$396M Buy
3,170,471
+986,520
+45% +$118M 2.76% 13
2022
Q2 		$269M Buy
2,183,951
+570,610
+35% +$69.6M 1.59% 18
2022
Q1 		$260M Buy
1,613,341
+533,820
+49% +$104M 1.09% 23
2021
Q4 		$359M Buy
1,079,521
+498,750
+86% +$237M 1.08% 27
2021
Q3 		$269M Buy
+580,771
New +$283M 0.65% 39

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cathie Wood's DNA Position: Q3 2024 in Review

Cathie Wood sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 596,280 shares — an estimated $7.97M sold.

Cathie Wood first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $396M in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Cathie Wood reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Cathie Wood sold 596,280 Ginkgo Bioworks shares in Q3 2024, an estimated $7.97M.
  • Cathie Wood first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Cathie Wood's Ginkgo Bioworks position peaked at $396M in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on ARK Investment Management's 13F filing for Q3 2024, filed 31 Oct 2024.